Terremoto Biosciences has reeled in $175 million to create small molecules based on work from Principia Biopharma co-founder Jack Taunton and Global Blood Therapeutics co-founder Matthew Jacobson.
Jack Taunton The Series B arrives 18 months after the South San Francisco…
Click here to view original post
